Results 151 to 160 of about 66,044 (308)

The Netherlands

open access: yes, 2021
Vandenberghe, Hanne, d'Haenens, Leen
openaire   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

The Blackstone Group: A Case Study [PDF]

open access: yes
The Blackstone Group, Inc., located in Beaumont, Texas, is a full-service advertising agency providing design, media, and marketing support for clients in southeast Texas and the Lake Charles, Louisiana, area.
Carol J. Cumber   +3 more
core  

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

open access: yesMolecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix   +13 more
wiley   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Les correspondants de presse étrangère en France. Des modèles et des missions entre routines, bouleversements et paradoxes.

open access: yesSur le Journalisme, 2016
Cette contribution s’intéresse aux correspondants étrangers exerçant en France, assez peu étudiés. La réflexion proposée repose en grande partie sur une vingtaine d’entretiens avec les journalistes eux‑mêmes, travaillant à Paris pour différents pays et ...
Jérémie Nicey
doaj  

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Multiplication des statuts précaires et (dé)structuration de l’espace professionnel

open access: yesSur le Journalisme, 2013
Cet article vise à interroger les formes d’encadrement du marché du travail du journalisme, la diversification des statuts d’emploi qui y ont cours et ses effets sur l’espace professionnel.
Cégolène Frisque
doaj  

Home - About - Disclaimer - Privacy